Cytek Biosciences, Inc. (CTKB) Stock Price & Analysis
Cytek Biosciences, Inc. (CTKB) rose 2.23% to USD 4.13 as of June 10, 2026 at 00:42 UTC, according to Nexqual real-time market data.
CTKB last closed at USD 4.04; the session ranged USD 4–4.15 on volume of 1,341,585 shares. Market capitalization is $533.36M, with a 52-week range of USD 2.9–6.18 (NMS). Source: Nexqual, June 10, 2026 at 00:42 UTC.
Key Statistics (as of June 10, 2026 at 00:42 UTC)
| Price | USD 4.13 |
|---|---|
| Change | ▲ 2.23% (up) |
| Previous Close | USD 4.04 |
| Open | USD 4.06 |
| Day Range | USD 4 – 4.15 |
| 52-Week Range | USD 2.9 – 6.18 |
| Volume | 1,341,585 shares |
| Market Cap | $533.36M |
| Exchange | NMS |
Technical Analysis (CTKB)
Nexqual's technical model rates CTKB "NEUTRAL" based on 2 bullish and 3 bearish signals across 124 daily candles, as of June 10, 2026 at 00:42 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 49.18 (neutral) |
| vs SMA50 | Below (USD 4.31) |
| MACD | -0.04 (negative) |
Analyst Ratings (CTKB)
Wall Street analysts rate CTKB "None" based on 4 analysts, with a mean price target of USD 5.69 (range USD 4.75–7.5), per Nexqual as of June 10, 2026 at 00:42 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 5.69 |
| High Target | USD 7.5 |
| Low Target | USD 4.75 |
| Buy / Hold / Sell | 2 / 2 / 0 |
Earnings (CTKB)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.01 |
| Revenue Estimate | $48.61M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.1 vs est -0.08 ▼ miss |
| 2025-12-31 | USD -0.29 vs est 0.02 ▼ miss |
| 2025-09-30 | USD -0 vs est 0.01 ▼ miss |
| 2025-06-30 | USD -0.01 vs est -0.02 ▲ beat |
Source: Nexqual, June 10, 2026 at 00:42 UTC.
Financials & Fundamentals (CTKB)
| Total Revenue | $204.17M |
|---|---|
| Revenue Growth (YoY) | +6.50% |
| Gross Margin | +51.70% |
| Operating Margin | -41.83% |
| Profit Margin | -36.25% |
| ROE | -20.93% |
| Debt / Equity | 8.39 |
| Current Ratio | 4.69 |
| Total Cash | $262.22M |
| Total Debt | $27.48M |
| Free Cash Flow | $6.41M |
Source: Nexqual, June 10, 2026 at 00:42 UTC.
Financial Health Score (CTKB)
Nexqual rates Cytek Biosciences, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 00:42 UTC.
| Growth | Mixed — Revenue +0.5% YoY (annual), slow |
|---|---|
| Profitability | Mixed — Gross margin 52%, operating -42% |
| Balance Sheet | Strong — $262M cash vs $27M debt, net cash position |
| Cash Flow | Mixed — FCF $6M, slim 3.2% margin |
| Efficiency | Critical — ROE -21%, ROA -5.9% |
Ownership (CTKB)
| Insider Ownership | +8.38% |
|---|---|
| Institutional Ownership | +67.58% |
| Shares Outstanding | 129.14M |
| Float | 96.62M |
| Short % of Float | +6.74% |
Source: Nexqual, June 10, 2026 at 00:42 UTC.
Leadership (CTKB)
Cytek Biosciences, Inc. is led by Wenbin Jiang (age 61), President, CEO & Chairman of the Board, per Nexqual as of June 10, 2026 at 00:42 UTC.
| President, CEO & Chairman of the Board | Wenbin Jiang (age 61) |
|---|---|
| Chief Financial Officer | William D. McCombe (age 67) |
| CTO & Director | Ming Yan (age 62) |
Major Backers & Investors (CTKB)
Notable institutional backers of Cytek Biosciences, Inc. include Topline Capital Management, LLC, HHLR Advisors, LTD, Millennium Management, according to Nexqual as of June 10, 2026 at 00:42 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Topline Capital Management, LLC | 5.47% |
| HHLR Advisors, LTD | 5.15% |
| Millennium Management | 4.87% |
| Boston Partners | 4.49% |
| Goldman Sachs | 1.82% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 21.33% |
| Vanguard Group | 7.28% |
| State Street | 3.95% |
| Geode Capital | 2.19% |
| Dimensional Fund Advisors | 2.06% |
Source: Nexqual, June 10, 2026 at 00:42 UTC.
From Cytek Biosciences, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Each system is supported by our highly intuitive, proprietary embedded SpectroFlo ® software, our reagents, and our service offerings to provide a comprehensive, end-to-end platform of solutions for our customers.
- In addition to pursuing patents on our technology, we have taken steps to protect our intellectual property and proprietary technology by entering into confidentiality agreements and intellectual property assignment agreements with our employees, consultants, corporate partners and, when needed, our advisors.
- For example, we utilize both instructor-led training and online learning to deliver proprietary, targeted training courses designed to position our commercial organization as the leading cell analysis solutions provider.
- Our proprietary tools and the intuitive functionality of our proprietary SpectroFlo software coupled with a user-friendly interface allow for enhanced ease-of-use and minimal operator training.
Partnerships
- On October 6, 2020, we entered into a Settlement, License and Equity Issuance Agreement with BD pursuant to which we and BD agreed to a mutual release of all claims against each other as of the date thereof (the "BD Agreement").
- Our Panel Builder tool combines all the features of the Full Spectrum Viewer with additional tools for panel design and collaboration in a simple and organized interface.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SGHT | Sight Sciences, Inc. | USD 4.85 | ▲ 8.99% |
| TMCI | Treace Medical Concepts, Inc. | USD 3.73 | ▲ 6.27% |
| DSGN | Design Therapeutics, Inc. | USD 10.55 | ▼ 0.94% |
| RPID | Rapid Micro Biosystems, Inc. | USD 1.88 | ▼ 5.53% |
| EVCM | EverCommerce Inc. | USD 9 | ▼ 2.17% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:42 UTC. This page is informational and not investment advice.